Leronlimab Phase 1b/2 Trial Dosing Flowchart
Patient
Leronlimab Phase 1b/2 Trial Dosing Flowchart
Patient Enrollment & Dose Escalation Plan:
First 3 patients
Starting dose: 350 mg leronlimab
42-day safety observation period
2 circulating tumor cell (CTC) tests performed
Next 3 patients
Starting dose: 525 mg leronlimab
42-day safety observation period
2 CTC tests performed
Next 3 patients
Starting dose: 700 mg leronlimab
42-day safety observation period
FDA Safety Review
After sufficient safety data, FDA authorized 700 mg as safe moving forward.
Patient Dosing After FDA Approval:
First 6 patients (350 mg and 525 mg cohorts):
Most likely remained on their original doses.
No clear memory or record of mandatory dose escalation to 700 mg.
Standard practice: unless protocol amendment and patient consent, doses typically stay stable.
New patients post-FDA approval:
Started directly on 700 mg leronlimab.
Current CRC Trial Comparison:
Start at lower doses (per protocol).
After Safety Committee review, escalate all patients to 700 mg if no safety concerns.
Visual Timeline:
Stage
Dose
Action After 42 Days
First 3 patients
350 mg
If safe, proceed to next dose level
Next 3 patients
525 mg
If safe, proceed to next dose level
Next 3 patients
700 mg
Continue at 700 mg
FDA Safety Clearance
-
Future patients start at 700 mg
Notes:
If patients showed good tolerability and no serious adverse events, the escalation proceeded.
Historical records or trial protocols would definitively confirm whether earlier patients escalated.
Summary:
It is most likely that the first 6 patients in the trial remained at their initial doses (350 mg or 525 mg) and only new patients after FDA clearance were started directly at 700 mg
11
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...
Continue Reading
Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...
Continue Reading
Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...
Continue Reading
When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...
Continue Reading
Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...
Continue Reading
Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...
Continue Reading
Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....
Continue Reading
A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...
Continue Reading
A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...
Continue Reading
Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...
Continue Reading
Top 5 Most Recently Viewed Articles
Celebrating 20 Years of Automotive Photography Renowned automotive photographer Larry Chen presents his first-ever book titled Life at Shutter Speed: Two Decades of Larry Chen Photography. This extensive 400-page work features exceptional highlights from Chen's impressive career, along with captivating never-before-seen images. What’s Inside the Book? Life at Shutter...
Continue Reading
Kemper Corporation Achieves New Stock Milestone Kemper Corporation (NYSE: KMPR) has reached an impressive milestone by achieving a remarkable 52-week high of $71.71. This achievement not only signifies a substantial uptrend for the diversified insurance holding but also reflects a commendable 67.95% increase in its stock value over the past year. The rising confidence...
Continue Reading
Challenges Faced by Local Convenience Stores in Quebec Local convenience stores in Quebec are confronting significant challenges due to the rise of online vaping sales. As these businesses grapple with a ban on flavored vapor products, introduced by Health Minister Christian Dubé, they are witnessing a shift in consumer behavior. This change has driven many customers to...
Continue Reading
Krispy Kreme Investors: The Class Action Lawsuit Explained Krispy Kreme, Inc. (NASDAQ: DNUT) is facing a class action lawsuit that is generating significant attention among investors. This suit has been initiated by Robbins LLP following concerns about misleading statements made by the company's executives regarding its partnership with McDonald's. For anyone invested in...
Continue Reading
Important Warning for DexCom, Inc. Shareholders Investors holding shares of DexCom, Inc. (NASDAQ: DXCM) should be aware of a critical opportunity to engage in a class action lawsuit. This notice emphasizes the essential details for shareholders who purchased shares during the specified class period. Your Participation Matters Shareholders are urged to reach out promptly...
Continue Reading